UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)

N/AUnknownNCT06080386

University Hospital, Angers100 enrolled

Overview

The purpose of this study is to assess UDFF performance (compared to MRI)

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Non Alcoholic Fatty Liver Disease

Interventions

UDFFDIAGNOSTIC_TEST

quantification of liver fat: UDFF (lipid fraction derived from ultrasound) from one of the probes of an ultrasound system

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients who had hepatic ultrasound with available UDFF measurements and hepatic MRI (with steatosis quantification sequences) between 01/01/2022 and 31/09/2023 may be included. Exclusion Criteria: * chronic liver disease with a different etiology other than NAFL/NASH or mixed (hepatitis B or C, hemochromatosis, autoimmune hepatitis, Wilson's disease, cholestasic disease, alpha 1 antitrypsin deficiency), * decompensated cirrhosis (ascites, jaundice, encephalopathy, rupture of esophageal varices), * hepatocellular carcinoma. * opposition to the use of its data

Locations (1)

Angers university hospital

Angers, France

RECRUITING

Outcomes

Primary Outcomes

To evaluate the perfomances of the UDFF system for the quantification of hepatic steatosis in patients suspected of chronic hepatophyte.

Steatosis value measured by multiecho sequences in MR

Time frame: 3 months maximum between the 2 measurements (UDFF and MRi)

Central Contacts

Christophe Aubé

CONTACT

+33 2 41 35 42 81 chaube@chu-angers.fr

Marie Bost

CONTACT

+33 2 41 35 31 99 mabost@chu-angers.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.